This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): JNJ54861911, JNJ 54861911
Description: JNJ-54861911 prevents amyloid precursor protein cleavage by inhibiting the enzyme BACE.
Shionogi and Janssen
In October 2012, Shionogi entered into a license agreement with Janssen Pharmaceuticals for a research collaboration and for the development and commercialization of oral beta-secretase (BACE) inhibitors for the treatment of Alzheimers disease. Janssen will conduct the clinical development work under the agreement.
Under the terms of this agreement, the oral BACE inhibitor compounds discovered by Shionogi, including the lead drug candidates, will be licensed to Janssen. Shionogi and Janssen will also jointly conduct a research collaboration for back-up oral small molecules. In the event that one or more of these back-up compounds are selected for clinical studies, Janssen will conduct the development in accordance with mutually agreed plans.
Shionogi will receive an upfront payment from Janssen. Shionogi also is eligible to receive milestone payments from Janssen upon successful completion of key development phases, including marketing...See full deal structure in Biomedtracker
Partners: Shionogi & Co. Ltd.
Additional information available to subscribers only: